Skip to main content
. 2019 Mar 2;39:7. doi: 10.1186/s40880-019-0354-z

Fig. 1.

Fig. 1

Kaplan-Meier curves of the progression-free survival (PFS) and overall survival (OS) for NSCLC patients with EGFR signaling pathway alterations. PFS (a) and OS (b) were analyzed in the 416 NSCLC patients, according to the EGFR signaling pathway alterations. In the 156 NSCLC patients with EGFR mutation, PFS (c) and OS (d) were analyzed according to the EGFR signaling pathway alterations. The survival rates were compared using the log-rank test. NSCLC non-small cell lung cancer, PFS progression-free survival, OS overall survival